As long as the physician's mantra "first, do no harm" is not broken, and there is an unmet clinical need, early approval is possible. Safety is key - and looks very good in our case. Also some efficacy data which is a bonus. Therefore I agree that there is a definite possibility of getting to market expediently.
As long as the physician's mantra "first, do no harm" is not...
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.47 |
Change
-1.120(7.18%) |
Mkt cap ! $1.854B | |||
| Open | High | Low | Value | Volume |
| $15.38 | $15.40 | $14.40 | $9.160M | 624.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50 | $14.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.55 | 1764 | 2 |
View Market Depth
| Last trade - 16.10pm 02/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |